{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:17:44Z","timestamp":1793236664400,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["LCG002\u2013SPARK II"],"award-info":[{"award-number":["LCG002\u2013SPARK II"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["LCG002\u2013SPARK II"],"award-info":[{"award-number":["LCG002\u2013SPARK II"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["LCG002\u2013SPARK II"],"award-info":[{"award-number":["LCG002\u2013SPARK II"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/OFIRG\/0074\/2018"],"award-info":[{"award-number":["NMRC\/OFIRG\/0074\/2018"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["LCG002\u2013SPARK II"],"award-info":[{"award-number":["LCG002\u2013SPARK II"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Parkinson\u2019s disease (PD) and dementia with Lewy bodies (DLB) are common age-related neurodegenerative diseases comprising Lewy body spectrum disorders associated with cortical and subcortical Lewy body pathology. Over 30% of PD patients develop PD dementia (PDD), which describes dementia arising in the context of established idiopathic PD. Furthermore, Lewy bodies frequently accompany the amyloid plaque and neurofibrillary tangle pathology of Alzheimer\u2019s disease (AD), where they are observed in the amygdala of approximately 60% of sporadic and familial AD. While PDD and DLB share similar pathological substrates, they differ in the temporal onset of motor and cognitive symptoms; however, protein markers to distinguish them are still lacking.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Here, we systematically studied a series of AD and PD pathogenesis markers, as well as mitochondria, mitophagy, and neuroinflammation-related indicators, in the substantia nigra (SN), temporal cortex (TC), and caudate and putamen (CP) regions of human post-mortem brain samples from individuals with PDD and DLB and condition-matched controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that p-APP<jats:sup>T668<\/jats:sup> (TC), \u03b1-synuclein (CP), and LC3II (CP) are all increased while the tyrosine hydroxylase (TH) (CP) is decreased in both PDD and DLB compared to control. Also, the levels of A\u03b242 and DD2R, IBA1, and p-LRRK2<jats:sup>S935<\/jats:sup> are all elevated in PDD compared to control. Interestingly, protein levels of p-Tau<jats:sup>S199\/202<\/jats:sup> in CP and DD2R, DRP1, and VPS35 in TC are all increased in PDD compared to DLB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Together, our comprehensive and systematic study identified a set of signature proteins that will help to understand the pathology and etiology of PDD and DLB at the molecular level.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12868-021-00687-4","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T10:08:03Z","timestamp":1641290883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Increased expression of pathological markers in Parkinson\u2019s disease dementia post-mortem brains compared to dementia with Lewy bodies"],"prefix":"10.1186","volume":"23","author":[{"given":"Haitao","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook-Yoong","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline S. L.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng-King","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"12","key":"687_CR1","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord. 2007;22(12):1689\u2013707.","journal-title":"Mov Disord"},{"issue":"6","key":"687_CR2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20\u00a0years. Mov Disord. 2008;23(6):837\u201344.","journal-title":"Mov Disord"},{"issue":"7","key":"687_CR3","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/arclin\/acx085","volume":"32","author":"JA Fields","year":"2017","unstructured":"Fields JA. Cognitive and neuropsychiatric features in Parkinson\u2019s and Lewy body dementias. Arch Clin Neuropsychol. 2017;32(7):786\u2013801.","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"687_CR4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"1","key":"687_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-018-0350-6","volume":"10","author":"JPM Kane","year":"2018","unstructured":"Kane JPM, Surendranathan A, Bentley A, Barker SAH, Taylor J-P, Thomas AJ, Allan LM, McNally RJ, James PW, McKeith IG, et al. Clinical prevalence of Lewy body dementia. Alzheimers Res Ther. 2018;10(1):19\u201319.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"687_CR6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"SA Vann Jones","year":"2013","unstructured":"Vann Jones SA, O\u2019Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2013;44(4):673\u201383.","journal-title":"Psychol Med"},{"issue":"9","key":"687_CR7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp.74.9.1215","volume":"74","author":"D Aarsland","year":"2003","unstructured":"Aarsland D. Performance on the dementia rating scale in Parkinson\u2019s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1215\u201320.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"687_CR8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fneur.2018.00123","volume":"9","author":"GM Aldridge","year":"2018","unstructured":"Aldridge GM, Birnschein A, Denburg NL, Narayanan NS. Parkinson\u2019s disease dementia and dementia with Lewy bodies have similar neuropsychological profiles. Front Neurol. 2018;9:123\u2013123.","journal-title":"Front Neurol"},{"issue":"5","key":"687_CR9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457\u201364.","journal-title":"Ann Neurol"},{"issue":"4","key":"687_CR10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00221-010-2182-x","volume":"201","author":"PE Gottschall","year":"2010","unstructured":"Gottschall PE, Ajmo JM, Eakin AK, Howell MD, Hina M, Bailey LA. Panel of synaptic protein ELISAs for evaluating neurological phenotype. Exp Brain Res. 2010;201(4):885\u201393.","journal-title":"Exp Brain Res"},{"issue":"5","key":"687_CR11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/brain\/awr031","volume":"134","author":"Y Compta","year":"2011","unstructured":"Compta Y, Parkkinen L, O\u2019Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, et al. Lewy- and Alzheimer-type pathologies in Parkinson\u2019s disease dementia: which is more important? Brain. 2011;134(5):1493\u2013505.","journal-title":"Brain"},{"issue":"11","key":"687_CR12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jalz.2016.04.005","volume":"12","author":"E Bereczki","year":"2016","unstructured":"Bereczki E, Francis PT, Howlett D, Pereira JB, H\u00f6glund K, Bogstedt A, Cedazo-Minguez A, Baek J-H, Hortob\u00e1gyi T, Attems J, et al. Synaptic proteins predict cognitive decline in Alzheimer\u2019s disease and Lewy body dementia. Alzheimers Dement. 2016;12(11):1149\u201358.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"687_CR13","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/brain\/awx352","volume":"141","author":"E Bereczki","year":"2018","unstructured":"Bereczki E, Branca RM, Francis PT, Pereira JB, Baek J-H, Hortob\u00e1gyi T, Winblad B, Ballard C, Lehti\u00f6 J, Aarsland D. Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain. 2018;141(2):582\u201395.","journal-title":"Brain"},{"issue":"2","key":"687_CR14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/brain\/awx344","volume":"141","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Perera G, Takahashi-Fujigasaki J, Mash DC, Vonsattel JPG, Uchino A, Hasegawa K, Jeremy Nichols R, Holton JL, Murayama S, et al. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. Brain. 2018;141(2):486\u201395.","journal-title":"Brain"},{"issue":"7113","key":"687_CR15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"MT Lin","year":"2006","unstructured":"Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787\u201395.","journal-title":"Nature"},{"issue":"10","key":"687_CR16","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00415-011-6104-z","volume":"258","author":"M Filosto","year":"2011","unstructured":"Filosto M, Scarpelli M, Cotelli MS, Vielmi V, Todeschini A, Gregorelli V, Tonin P, Tomelleri G, Padovani A. The role of mitochondria in neurodegenerative diseases. J Neurol. 2011;258(10):1763\u201374.","journal-title":"J Neurol"},{"issue":"1","key":"687_CR17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cell.2008.06.016","volume":"134","author":"DJ Pagliarini","year":"2008","unstructured":"Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong S-E, Walford GA, Sugiana C, Boneh A, Chen WK, et al. A Mitochondrial protein compendium elucidates complex I disease biology. Cell. 2008;134(1):112\u201323.","journal-title":"Cell"},{"issue":"1","key":"687_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cns.12655","volume":"23","author":"M Golpich","year":"2017","unstructured":"Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment. CNS Neurosci Ther. 2017;23(1):5\u201322.","journal-title":"CNS Neurosci Ther"},{"issue":"4","key":"687_CR19","doi-asserted-by":"crossref","first-page":"824.e825","DOI":"10.1016\/j.neurobiolaging.2011.04.011","volume":"33","author":"RO Costa","year":"2012","unstructured":"Costa RO, Ferreiro E, Martins I, Santana I, Cardoso SM, Oliveira CR, Pereira CMF. Amyloid \u03b2-induced ER stress is enhanced under mitochondrial dysfunction conditions. Neurobiol Aging. 2012;33(4):824.e825-824.e816.","journal-title":"Neurobiol Aging"},{"issue":"29","key":"687_CR20","doi-asserted-by":"crossref","first-page":"10726","DOI":"10.1073\/pnas.0403649101","volume":"101","author":"PE Coskun","year":"2004","unstructured":"Coskun PE, Beal MF, Wallace DC. Alzheimer\u2019s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci. 2004;101(29):10726\u201331.","journal-title":"Proc Natl Acad Sci"},{"issue":"23","key":"687_CR21","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1093\/hmg\/dds360","volume":"21","author":"M Manczak","year":"2012","unstructured":"Manczak M, Reddy PH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer\u2019s disease. Hum Mol Genet. 2012;21(23):5131\u201346.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"687_CR22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1523\/JNEUROSCI.2507-13.2014","volume":"34","author":"C Guardia-Laguarta","year":"2013","unstructured":"Guardia-Laguarta C, Area-Gomez E, Rub C, Liu Y, Magrane J, Becker D, Voos W, Schon EA, Przedborski S. Synuclein Is localized to mitochondria-associated ER membranes. J Neurosci. 2013;34(1):249\u201359.","journal-title":"J Neurosci"},{"issue":"1","key":"687_CR23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/cdd.2012.81","volume":"20","author":"G Ashrafi","year":"2012","unstructured":"Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ. 2012;20(1):31\u201342.","journal-title":"Cell Death Differ"},{"issue":"3","key":"687_CR24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tins.2017.01.002","volume":"40","author":"JS Kerr","year":"2017","unstructured":"Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, Fang EF. Mitophagy and Alzheimer\u2019s disease: cellular and molecular mechanisms. Trends Neurosci. 2017;40(3):151\u201366.","journal-title":"Trends Neurosci"},{"issue":"4","key":"687_CR25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2174\/187152712800792901","volume":"11","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Zhang J, Zeng Y. Overview of tyrosine hydroxylase in Parkinson\u2019s disease. CNS Neurol Disord Drug Targets. 2012;11(4):350\u20138.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"4","key":"687_CR26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00702-018-1903-3","volume":"126","author":"T Nagatsu","year":"2019","unstructured":"Nagatsu T, Nakashima A, Ichinose H, Kobayashi K. Human tyrosine hydroxylase in Parkinson\u2019s disease and in related disorders. J Neural Transm. 2019;126(4):397\u2013409.","journal-title":"J Neural Transm"},{"issue":"5321","key":"687_CR27","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH. Mutation in the-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276(5321):2045\u20137.","journal-title":"Science"},{"issue":"6645","key":"687_CR28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. \u03b1-Synuclein in Lewy bodies. Nature. 1997;388(6645):839\u201340.","journal-title":"Nature"},{"issue":"7","key":"687_CR29","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/brain\/aww109","volume":"139","author":"M Masellis","year":"2016","unstructured":"Masellis M, Collinson S, Freeman N, Tampakeras M, Levy J, Tchelet A, Eyal E, Berkovich E, Eliaz RE, Abler V, et al. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study. Brain. 2016;139(7):2050\u201362.","journal-title":"Brain"},{"issue":"2","key":"687_CR30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1042\/AN20120066","volume":"5","author":"V Sanchez-Guajardo","year":"2013","unstructured":"Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M. Neuroimmunological processes in Parkinson\u2019s disease and their relation to \u03b1-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro. 2013;5(2):113\u201339.","journal-title":"ASN Neuro"},{"issue":"1","key":"687_CR31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2009.01.038","volume":"137","author":"K Saijo","year":"2009","unstructured":"Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, Gage FH, Glass CK. A Nurr1\/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009;137(1):47\u201359.","journal-title":"Cell"},{"issue":"3","key":"687_CR32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.molmed.2010.11.002","volume":"17","author":"C Vives-Bauza","year":"2011","unstructured":"Vives-Bauza C, Przedborski S. Mitophagy: the latest problem for Parkinson\u2019s disease. Trends Mol Med. 2011;17(3):158\u201365.","journal-title":"Trends Mol Med"},{"issue":"5","key":"687_CR33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/cells7050037","volume":"7","author":"A Metaxakis","year":"2018","unstructured":"Metaxakis A, Ploumi C, Tavernarakis N. Autophagy in age-associated neurodegeneration. Cells. 2018;7(5):37.","journal-title":"Cells"},{"issue":"4","key":"687_CR34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1468-1331.2007.01685.x","volume":"14","author":"SN Illarioshkin","year":"2007","unstructured":"Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GK, Markova ED, Limborska SA, Ivanova-Smolenskaya IA. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson\u2019s disease in Russia. Eur J Neurol. 2007;14(4):413\u20137.","journal-title":"Eur J Neurol"},{"key":"687_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddx337","author":"Z Chen","year":"2017","unstructured":"Chen Z, Cao Z, Zhang W, Gu M, Zhou ZD, Li B, Li J, Tan EK, Zeng L. LRRK2 interacts with ATM and regulates Mdm2-p53 cell proliferation axis in response to genotoxic stress. Human Mol Genet. 2017. https:\/\/doi.org\/10.1093\/hmg\/ddx337.","journal-title":"Human Mol Genet"},{"issue":"488","key":"687_CR36","doi-asserted-by":"crossref","first-page":"eaam6790","DOI":"10.1126\/scisignal.aam6790","volume":"10","author":"Z-C Chen","year":"2017","unstructured":"Chen Z-C, Zhang W, Chua L-L, Chai C, Li R, Lin L, Cao Z, Angeles DC, Stanton LW, Peng J-H, et al. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson\u2019s disease. Sci Signal. 2017;10(488):eaam6790.","journal-title":"Sci Signal"},{"issue":"15","key":"687_CR37","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/hmg\/ddx179","volume":"26","author":"T Inoshita","year":"2017","unstructured":"Inoshita T, Hattori N, Imai Y, Arano T, Hosaka Y, Meng H, Umezaki Y, Kosugi S, Morimoto T, Koike M, et al. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila. Hum Mol Genet. 2017;26(15):2933\u201348.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"687_CR38","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1042\/BCJ20180248","volume":"475","author":"R Mir","year":"2018","unstructured":"Mir R, Tonelli F, Lis P, Macartney T, Polinski NK, Martinez TN, Chou M-Y, Howden AJM, K\u00f6nig T, Hotzy C, et al. The Parkinson\u2019s disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochem J. 2018;475(11):1861\u201383.","journal-title":"Biochem J"},{"issue":"3","key":"687_CR39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41593-018-0332-9","volume":"22","author":"EF Fang","year":"2019","unstructured":"Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, Lautrup S, Hasan-Olive MM, Caponio D, Dan X, et al. Mitophagy inhibits amyloid-\u03b2 and tau pathology and reverses cognitive deficits in models of Alzheimer\u2019s disease. Nat Neurosci. 2019;22(3):401\u201312.","journal-title":"Nat Neurosci"},{"issue":"3","key":"687_CR40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mds.27601","volume":"34","author":"F Atashrazm","year":"2018","unstructured":"Atashrazm F, Hammond D, Perera G, Bolliger MF, Matar E, Halliday GM, Sch\u00fcle B, Lewis SJG, Nichols RJ, Dzamko N. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson\u2019s disease patients. Mov Disord. 2018;34(3):406\u201315.","journal-title":"Mov Disord"},{"issue":"10","key":"687_CR41","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.biopsych.2008.02.016","volume":"64","author":"L Parnetti","year":"2008","unstructured":"Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D\u2019Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P. Cerebrospinal fluid biomarkers in Parkinson\u2019s disease with dementia and dementia with Lewy bodies. Biol Psychiatry. 2008;64(10):850\u20135.","journal-title":"Biol Psychiatry"},{"issue":"15","key":"687_CR42","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/mds.23287","volume":"25","author":"TJ Montine","year":"2010","unstructured":"Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, et al. CSF A\u03b242and tau in Parkinson\u2019s disease with cognitive impairment. Mov Disord. 2010;25(15):2682\u20135.","journal-title":"Mov Disord"},{"issue":"1","key":"687_CR43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JAD-160322","volume":"54","author":"I van Steenoven","year":"2016","unstructured":"van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, et al. Cerebrospinal fluid Alzheimer\u2019s disease biomarkers across the spectrum of Lewy body diseases: results from a large multicenter cohort. J Alzheimers Dis. 2016;54(1):287\u201395.","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"687_CR44","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archneur.60.9.1218","volume":"60","author":"E G\u00f3mez-Tortosa","year":"2003","unstructured":"G\u00f3mez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemill\u00e1n C, Y\u00e9benes JG, del Ser T. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol. 2003;60(9):1218\u201322.","journal-title":"Arch Neurol"},{"issue":"10","key":"687_CR45","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jnen\/nlw070","volume":"75","author":"DH Hepp","year":"2016","unstructured":"Hepp DH, Vergoossen DL, Huisman E, Lemstra AW, Bank NB, Berendse HW, Rozemuller AJ, Foncke EM, van de Berg WD. Distribution and load of amyloid-\u03b2 pathology in Parkinson disease and dementia with Lewy bodies. J Neuropathol Exp Neurol. 2016;75(10):936\u201345.","journal-title":"J Neuropathol Exp Neurol"},{"key":"687_CR46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.neurobiolaging.2018.08.007","volume":"72","author":"Y-G Lee","year":"2018","unstructured":"Lee Y-G, Jeon S, Yoo HS, Chung SJ, Lee S-K, Lee PH, Sohn YH, Yun M, Evans AC, Ye BS. Amyloid-\u03b2-related and unrelated cortical thinning in dementia with Lewy bodies. Neurobiol Aging. 2018;72:32\u20139.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"687_CR47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/gps.2496","volume":"26","author":"M Andersson","year":"2011","unstructured":"Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson\u2019s disease dementia. Int J Geriatr Psychiatry. 2011;26(1):100\u20135.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"687_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"A Esteves","year":"2020","unstructured":"Esteves A, Cardoso S. Differential protein expression in diverse brain areas of Parkinson\u2019s and Alzheimer\u2019s disease patients. Sci Rep. 2020;10(1):1\u201322.","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"687_CR49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1006896111280","volume":"189","author":"GT Ramesh","year":"1998","unstructured":"Ramesh GT, Jadhav AL. Region-specific alterations in tyrosine hydroxylase activity in rats exposed to lead. Mol Cell Biochem. 1998;189(1\u20132):19\u201324.","journal-title":"Mol Cell Biochem"},{"issue":"15","key":"687_CR50","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1212\/WNL.0000000000003810","volume":"88","author":"L Saari","year":"2017","unstructured":"Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology. 2017;88(15):1461\u20137.","journal-title":"Neurology"},{"issue":"10","key":"687_CR51","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/1545968316650426","volume":"30","author":"I Maidan","year":"2016","unstructured":"Maidan I, Nieuwhof F, Bernad-Elazari H, Reelick MF, Bloem BR, Giladi N, Deutsch JE, Hausdorff JM, Claassen JAH, Mirelman A. The role of the frontal lobe in complex walking among patients with Parkinson\u2019s disease and healthy older adults. Neurorehabil Neural Repair. 2016;30(10):963\u201371.","journal-title":"Neurorehabil Neural Repair"},{"key":"687_CR52","doi-asserted-by":"crossref","first-page":"104633","DOI":"10.1016\/j.nbd.2019.104633","volume":"134","author":"JJ Lebowitz","year":"2020","unstructured":"Lebowitz JJ, Khoshbouei H. Heterogeneity of dopamine release sites in health and degeneration. Neurobiol Dis. 2020;134:104633.","journal-title":"Neurobiol Dis"},{"key":"687_CR53","first-page":"115","volume":"10","author":"Y Du","year":"2016","unstructured":"Du Y, Guo Q, Shan M, Wu Y, Huang S, Zhao H, Hong H, Yang M, Yang X, Ren L. Spatial and temporal distribution of dopaminergic neurons during development in zebrafish. Front Neuroanat. 2016;10:115.","journal-title":"Front Neuroanat"},{"issue":"24","key":"687_CR54","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1016\/j.febslet.2015.10.022","volume":"589","author":"A Anderegg","year":"2015","unstructured":"Anderegg A, Poulin J-F, Awatramani R. Molecular heterogeneity of midbrain dopaminergic neurons\u2014moving toward single cell resolution. FEBS Lett. 2015;589(24):3714\u201326.","journal-title":"FEBS Lett"},{"issue":"6","key":"687_CR55","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.tins.2013.03.003","volume":"36","author":"J Roeper","year":"2013","unstructured":"Roeper J. Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci. 2013;36(6):336\u201342.","journal-title":"Trends Neurosci"},{"key":"687_CR56","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.neuropharm.2013.03.019","volume":"76","author":"S Lammel","year":"2014","unstructured":"Lammel S, Lim BK, Malenka RC. Reward and aversion in a heterogeneous midbrain dopamine system. Neuropharmacology. 2014;76:351\u20139.","journal-title":"Neuropharmacology"},{"key":"687_CR57","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0345-18.2019","author":"JA Beeler","year":"2019","unstructured":"Beeler JA, Dreyer JK. Synchronicity: the role of midbrain dopamine in whole-brain coordination. Eneuro. 2019. https:\/\/doi.org\/10.1523\/ENEURO.0345-18.2019.","journal-title":"Eneuro"},{"issue":"6","key":"687_CR58","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.neuron.2016.08.018","volume":"91","author":"J Tian","year":"2016","unstructured":"Tian J, Huang R, Cohen JY, Osakada F, Kobak D, Machens CK, Callaway EM, Uchida N, Watabe-Uchida M. Distributed and mixed information in monosynaptic inputs to dopamine neurons. Neuron. 2016;91(6):1374\u201389.","journal-title":"Neuron"},{"issue":"9","key":"687_CR59","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/glia.23447","volume":"66","author":"DR Miller","year":"2018","unstructured":"Miller DR, Shaerzadeh F, Phan L, Sharif N, Gamble-George J, McLaughlin JP, Streit WJ, Khoshbouei H. HIV-1 T at regulation of dopamine transmission and microglial reactivity is brain region specific. Glia. 2018;66(9):1915\u201328.","journal-title":"Glia"},{"issue":"6","key":"687_CR60","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1074\/jbc.275.6.4159","volume":"275","author":"G Zauli","year":"2000","unstructured":"Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, Milani D, Dowd DR, Capitani S, Vitale M. HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem. 2000;275(6):4159\u201365.","journal-title":"J Biol Chem"},{"issue":"10","key":"687_CR61","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/mds.25493","volume":"28","author":"S Reyes","year":"2013","unstructured":"Reyes S, Cottam V, Kirik D, Double KL, Halliday GM. Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov Disord. 2013;28(10):1351\u20139.","journal-title":"Mov Disord"},{"key":"687_CR62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2014.01.025","volume":"282","author":"CP Ford","year":"2014","unstructured":"Ford CP. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience. 2014;282:13\u201322.","journal-title":"Neuroscience"},{"issue":"39","key":"687_CR63","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1523\/JNEUROSCI.2745-12.2012","volume":"32","author":"NA Courtney","year":"2012","unstructured":"Courtney NA, Mamaligas AA, Ford CP. Species differences in somatodendritic dopamine transmission determine D2-autoreceptor-mediated inhibition of ventral tegmental area neuron firing. J Neurosci. 2012;32(39):13520\u20138.","journal-title":"J Neurosci"},{"issue":"2","key":"687_CR64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.brainresrev.2008.02.004","volume":"58","author":"ME Rice","year":"2008","unstructured":"Rice ME, Cragg SJ. Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res Rev. 2008;58(2):303\u201313.","journal-title":"Brain Res Rev"},{"issue":"17","key":"687_CR65","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1093\/hmg\/ddu178","volume":"23","author":"E Tsika","year":"2014","unstructured":"Tsika E, Glauser L, Moser R, Fiser A, Daniel G, Sheerin UM, Lees A, Troncoso JC, Lewis PA, Bandopadhyay R, et al. Parkinson\u2019s disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum Mol Genet. 2014;23(17):4621\u201338.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"687_CR66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bpa.12182","volume":"25","author":"DR Howlett","year":"2015","unstructured":"Howlett DR, Whitfield D, Johnson M, Attems J, O\u2019Brien JT, Aarsland D, Lai MKP, Lee JH, Chen C, Ballard C, et al. Regional multiple pathology scores are associated with cognitive decline in Lewy body dementias. Brain Pathol. 2015;25(4):401\u20138.","journal-title":"Brain Pathol"},{"issue":"9","key":"687_CR67","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1101\/gr.106849.110","volume":"20","author":"M Somel","year":"2010","unstructured":"Somel M, Guo S, Fu N, Yan Z, Hu HY, Xu Y, Yuan Y, Ning Z, Hu Y, Menzel C. MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res. 2010;20(9):1207\u201318.","journal-title":"Genome Res"},{"issue":"3\u20134","key":"687_CR68","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/ars.2006.8.381","volume":"8","author":"HF Poon","year":"2006","unstructured":"Poon HF, Calabrese V, Calvani M, Butterfield DA. Proteomics analyses of specific protein oxidation and protein expression in aged rat brain and its modulation by L-acetylcarnitine: insights into the mechanisms of action of this proposed therapeutic agent for CNS disorders associated with oxidative stress. Antioxid Redox Signal. 2006;8(3\u20134):381\u201394.","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"687_CR69","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jnc.14037","volume":"143","author":"A Grimm","year":"2017","unstructured":"Grimm A, Eckert A. Brain aging and neurodegeneration: from a mitochondrial point of view. J Neurochem. 2017;143(4):418\u201331.","journal-title":"J Neurochem"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-021-00687-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12868-021-00687-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-021-00687-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T10:16:13Z","timestamp":1641291373000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/s12868-021-00687-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1186\/s12868-021-00687-4","relation":{},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human post-mortem tissues were obtained via a prospective donor scheme with fully informed written consent and their collection was approved by the UK Human Tissue Authority (Approval Number 18\/WA\/0238). This study was also approved by the Institutional Review Board (IRB) of the National Neuroscience Institute of Singapore and was performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}